Agenda FRIDAY, September 23, 2022

16th Annual Pacific Psychopharmacology Conference



TIME **PRESENTATION TITLE SPEAKER** 0730 Registration Opens | Breakfast Available Welcome & Opening Remarks 0820 Randall White, MD, FRCPC 0830 KEYNOTE: Treating Schizophrenia Better — From Neurobiology to Practice* Oliver Howes, MRCPsych, PhD, DM, FMedSci (In-person & Virtual) — Pinnacle Ballroom Professor of Molecular Psychiatry, • Review the nature of dopaminergic changes in schizophrenia Institute of Psychiatry, Psychology, & • Examine the neurobiology underlying treatment response and resistance Neuroscience, King's College London *Dr. Howes is delivering this lecture virtually from London, UK. 0915 **KEYNOTE: Emerging Directions in Depression Management** Sidney Kennedy, MD, FRCPC, (In-person & Virtual) — Pinnacle Ballroom FRCPsych, FCAHS, FRSC Professor of Psychiatry, University of Toronto; • Adopt a comprehensive approach to assessment Arthur Sommer Rotenberg Chair in Depression • Evaluate the role of emerging technologies in monitoring treatment outcomes and Suicide Studies, St. Michael's Hospital • Be aware of emerging therapeutic options for 'difficult to treat depression' 1000 **15-MIN REFRESHMENT BREAK** 1015 Antipsychotic Related Movement Disorders: An Overview and Update Tamara Pringsheim, MD, FRCPC (In-person & Virtual) — Pinnacle Ballroom Professor, Department of Clinical Neurosciences, Psychiatry, and Pediatrics, • Review the different types of movement disorders related to antipsychotic use, University of Calgary including real-life examples and video clips • Discuss the therapeutic management of antipsychotic related movement disorders, based on evidence-based recommendations from clinical guidelines 1100 Demystifying Pharmacogenetic Testing for Treatment Planning in Chad Bousman, MPH, PhD Associate Professor, Department of Medical Mood Disorders (In-person & Virtual) — Pinnacle Ballroom Genetics, University of Calgary; Head, • Summarize the evidence related to pharmacogenetic testing in mood disorders Psychiatric Pharmacogenomics (PsychPGx) Lab • Identify care situation where pharmacogenomics testing could be useful Critically assess the content, analytical, and clinical validity of a pharmaocogenomic test 75-MIN LUNCH BREAK 1145 1300 **CONCURRENT SESSION 1:** 1A) Practical Tips to Assess Antipsychotic Related Movement Tamara Pringsheim, MD, FRCPC Professor, Department of Clinical **Disorders for both In-person and Virtual Visits** Neurosciences, Psychiatry, Pediatrics and (In-person & Virtual) — Ballroom II

- Learn how to perform the Extrapyramidal Symptom Rating Scale correctly and with confidence
- Improve identification of antipsychotic related movement disorders through review of video clips



Calgary

1B) The Treatment of Adult ADHD in the Context of Stimulant Use and **Psychosis** (In-person & Virtual) — **Ballroom I**

- Examine the performance enhancing nature of stimulant medication
- Review the process of diagnosing and treating adult ADHD
- Compare the relationship between stimulants and psychosis
- Discuss how to treat psychosis in those with stimulant use disorder
- 1C) Navigating Pharmacogenomic Online Resources (In-person Only) — Port of Vancouver
- Identify key pharmacogenetic online resources
- Use pharmacogenetic online resources in clinical care situations



Nickie Mathew, MD, ABPN, FRCPC, ABPM

Community Health Sciences, University of

Clinical Associate Professor, Department of Psychiatry, UBC; Medical Director, Complex Mental Health and Substance Use Services, PHSA



Chad Bousman, PhD, MPH Associate Professor, Department of Medical Genetics, University of Calgary; Head, Psychiatric Pharmacogenomics (PsychPGx) Lab

Agenda FRIDAY, September 23, 2022



TIME PRESENTATION TITLE

1345 15-MIN REFRESHMENT BREAK

1400 **CONCURRENT SESSION 2:**

- 2A) Lessons from a QI Approach to Community Clozapine Challenges in Vancouver (*In-person Only*) Port of Vancouver
- Understand and plan for successful clozapine community management
- Identify the resources and how to tap into them to manage psychosis better in the community
- 2B) Antidepressant Induced Sexual Side Effects*

(In-person & Virtual) — Ballroom I

- Screen for the emergence of common sexual side effects of antidepressants
- Evaluate the interaction between sexual side effects of antidepressants and impact(s) of the primary depression
- Effectively communicate to patients how antidepressants impact sexual function
- *Rationally assess treatment options to reduce or eliminate the burden of sexual side effects*

*This session is NOT being recorded. Please attend LIVE if you wish to participate.

- 2C) Psychiatric Prescribing in Paediatric Autism (In-person Only) — Ballroom III
- *List 2 common psychiatric comorbidities of paediatric autism*
- Name the preferred medication to treat ADHD in the context of paediatric autism
- Identify behavioural treatment targets for antipsychotics in paediatric autism
- 2D) Emerging Adherence Technology: Factors to consider for homebased medication management (In-person & Virtual) — Ballroom II
- Compare features of emerging home-based medication dispensing & monitoring technology
- Discuss the potential advantages and disadvantages of the use of this technology
- Examine their place among options available to address medication adherence

1445 15-MIN REFRESHMENT BREAK

1545

1500 The Public Supply of Addictive Drugs

(In-person & Virtual) — Pinnacle Ballroom

- Summarize patient characteristics and risks associated with advocacy for PSAD
- Summarize evidence related to PSAD for at risk patients
- Outline empirically supported interventions that are indicated for patients at risk



SPEAKER

Harish Neelakant, MBBS, MD, FRCPC, FRCPsych (UK) *Clinical Assistant Professor, Department of Psychiatry, UBC*



Shauna Correia, MDCM, FRCPC Sexual Medicine Specialist, BC Center for Sexual Medicine, VCH; Clinical Instructor, Dept of Psychiatry (Sexual Medicine Program), UBC



Miriam Driscoll, MD, FRCPC Sexual Medicine Specialist, BC Center for Sexual Medicine, VCH; Clinical Assistant Professor, Dept of Psychiatry (Sexual Medicine Program), UBC



Francois Proulx, MD, FRCPC Child & Adolescent Psychiatrist, Medical Lead -Developmental Disorders & Mental Health Authority; Clinical Instructor, Department of Psychiatry, UBC



Tejal Patel, BScPharm, PharmD *Clinical Associate Professor and Co-Director, Master of Advanced Pharmacy Practice Program, University of Waterloo School of Pharmacy*



Julian Somers, MSc, PhD, RPsych Distinguished Professor and Clinical Psychologist, Faculty of Health Sciences, Simon Fraser University



Bernie Pauly, RN, PhD

(In-person & Virtual) — Pinnacle Ballroom

- Summarize evidence on the impacts of prescribed safer supply on health and wellness among people who use drugs
- Describe findings on implementation of prescribed safer supply in BC, including barriers and facilitators, from multiple stakeholder perspectives

Professor, School of Nursing, University of Victoria; Scientist, Canadian Institute for Substance Use Research



Karen Urbanoski, PhD Canada Research Chair and Associate Professor, Public Health and Social Policy, University of Victoria

1630 Closing Remarks | Conference Ends

Please complete the online evaluation forms before you depart. Thank you for joining us!

Jacky Siu, PharmD, ACPR, BCPP